Scientists have discovered a powerful new antibiotic hidden within the compound pre-methylenomycin C lactone, which shows real effectiveness against drug-resistant infections such as MRSA and VRE. Chemists from the University of Warwick and Monash University have uncovered a promising new antibiotic that could be a game-changer in the global fight against antimicrobial resistance (AMR). The compound, known as pre-methylenomycin C lactone, has demonstrated strong activity against drug-resistant pathogens, including MRSA and VRE. This discovery is particularly significant as AMR is one of the world's most pressing health challenges, with the World Health Organization (WHO) warning that there are 'too few antibacterials in the pipeline'. The new study found that the antibiotic was 'hiding in plain sight' as an intermediate chemical in the natural production of the well-known antibiotic methylenomycin A. This finding is groundbreaking because it suggests a new approach to antibiotic discovery, focusing on testing intermediates in the pathways to diverse natural compounds. The researchers discovered that pre-methylenomycin C lactone is over 100 times more effective against Gram-positive bacteria than methylenomycin A, especially targeting Staphylococcus aureus and Enterococcus faecium, the bacteria responsible for MRSA and VRE. One of the most encouraging aspects of this discovery is the resilience of pre-methylenomycin C lactone against resistance. The researchers did not detect any emergence of resistance to this compound in Enterococcus bacteria under conditions where vancomycin resistance is usually found, making it a promising candidate for tackling VRE. The next steps involve pre-clinical testing, and the researchers are optimistic about the potential of this new antibiotic. With its simple structure, potent activity, resilience to resistance, and scalable production, pre-methylenomycin C lactone could be a major breakthrough in antibiotic development. The scientists hope it may one day help save the lives of the 1.1 million people who die each year due to antimicrobial resistance.
